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Abstract
Background: In silico molecular docking is an essential step in modern drug discovery when driven by a well
defined macromolecular target. Hence, the process is called structure-based or rational drug design (RDD). In the
docking step of RDD the macromolecule or receptor is usually considered a rigid body. However, we know from
biology that macromolecules such as enzymes and membrane receptors are inherently flexible. Accounting for this
flexibility in molecular docking experiments is not trivial. One possibility, which we call a fully-flexible receptor
model, is to use a molecular dynamics simulation trajectory of the receptor to simulate its explicit flexibility. To
benefit from this concept, which has been known since 2000, it is essential to develop and improve new tools that
enable molecular docking simulations of fully-flexible receptor models.
Results: We have developed a Flexible-Receptor Docking Workflow System (FReDoWS) to automate molecular
docking simulations using a fully-flexible receptor model. In addition, it includes a snapshot selection feature to
facilitate acceleration the virtual screening of ligands for well defined disease targets. FReDoWS usefulness is
demonstrated by investigating the docking of four different ligands to flexible models of Mycobacterium
tuberculosis’ wild type InhA enzyme and mutants I21V and I16T. We find that all four ligands bind effectively to this
receptor as expected from the literature on similar, but wet experiments.
Conclusions: A work that would usually need the manual execution of many computer programs, and the
manipulation of thousands of files, was efficiently and automatically performed by FReDoWS. Its friendly interface
allows the user to change the docking and execution parameters. Besides, the snapshot selection feature allowed
the acceleration of docking simulations. We expect FReDoWS to help us explore more of the role flexibility plays in
receptor-ligand interactions. FReDoWS can be made available upon request to the authors.
Background
Today’s drug development costs have an estimated aver-
age of 800 million dollars per approved drug and the
time necessary to put it into the market is between 10
to 15 years [1]. Hence, there are efforts to change these
numbers, for example, by reducing the timeline and
costs, and increasing the quality of the candidate drugs.
An important step in the process of new drug discovery
is the improvement of our understanding about target
receptor-ligand interactions at the molecular level [2].
The advent of molecular biology, especially genomic
sciences, and the intensive use of computer simulation
tools over the past years, have had a deep impact on
d r u gd i s c o v e r y[ 3 ] ,t u r n i n gp o s s i b l eam o r er a t i o n a l
drug design (RDD) approach [4]. RDD basically involves
a four-step cycle that combines dry and wet experiments
with structure information [4]. Wet experiments are the
* Correspondence: osmar.norberto@pucrs.br
1LABIO - Laboratório de Bioinformática, Modelagem e Simulação de
Biossistemas. PPGCC, Faculdade de Informática, PUCRS, Av. Ipiranga, 6681 –
Prédio 32, Sala 602, 90619-900, Porto Alegre, RS, Brazil
Full list of author information is available at the end of the article
Machado et al. BMC Genomics 2011, 12(Suppl 4):S6
http://www.biomedcentral.com/1471-2164/12/S4/S6
© 2011 Machado et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.traditional assays performed in vitro and in vivo while
dry experiments are performed in silico or on
computers.
In the RDD’s first step the structure of the target
receptor (hereinafter receptor is used as synonymous of
macromolecule and protein) provides a starting point
for direct modeling activities. During this step, the
three-dimensional (3-D) structure of the receptor
obtained, for example, from the Protein Data Bank
(PDB) [5], is analyzed in order to identify probable bind-
ing sites. In the second step, based on such probable
binding sites, a set of possible ligands (hereinafter
ligand, inhibitor and small molecules have the same
meaning) is selected. It corresponds to filtering com-
pounds from a ligand database such as ZINC [6]. Subse-
quently, in the third step, the receptor-ligand
interactions are evaluated by computer simulations
using molecular docking software, of which AutoDock
[7], DOCK [8], and FlexE [9] are just a few examples.
Throughout this step the ligands that had the best inter-
action score to the receptor are selected, bought or
synthesized, and then wet-experimentally tested. Finally,
in the fourth step, based on the in vitro results, an inhi-
bitor candidate is detected, or the process returns to the
first step.
A detailed understanding of the interaction between
ligands and receptors, using molecular docking simula-
tions, constitutes the very basis of RDD [10]. It is during
molecular docking that the best ligand fit into the recep-
tor becomes available [4]. To assess the quality of the
ligand fitness, a large number of evaluations are carried
out to score and rank the best ligand conformation and
orientation inside the receptor binding pocket. Different
approaches, including force-field methods, empirical
scoring functions, and knowledge-based potentials have
been developed to score receptor-ligand interactions
[11]. In AutoDock3.0.5 [7], for example, the force-field
based scoring function is computed in terms of the esti-
m a t e df r e ee n e r g yo fb i n d i n g( F E B ) .T h em o r en e g a t i v e
the estimated FEB, the more effective is the ligand-
receptor association.
Most docking software is capable of simulating the
different conformations that the ligands can assume
inside the receptor binding pocket by considering their
flexibility [7,12]. As to the receptor, the state of the art
docking algorithms predict an incorrect binding pose for
about 50-70 % of all ligands when only a single, rigid
receptor conformation is considered [12]. However,
there are limitations to the use of the explicit flexibility
of the receptor [12-14] due to its large number of
degrees of freedom [12-16]. Moreover, from Biology we
know that receptors, such as proteins, enzymes, DNA,
and RNA are inherently flexible macromolecular sys-
tems [13,17] and this flexibility is often essential for
their functions [13]. Macromolecules can modify their
shape upon ligand binding, molding themselves to be
complementary to the ligand, increasing favorable con-
tacts and reducing adverse interactions, thus minimizing
the total FEB [13].
Receptor flexibility in molecular docking
There are a number of alternative ways to incorporate,
at least in part, the receptor flexibility in molecular
docking simulations (reviewed by Teodoro and Kavraki
[18], Totrov and Abagyan [12], Cozzini et al. [13],
Huang and Zou [15], Wong [16], Alonso et al. [17] and
Chandrika et al. [19]). Some methods consider only one
receptor conformation. However, there are approaches
that make use of a set of receptor conformations. Recep-
tor conformations can be determined experimentally
either by X-ray diffraction or NMR experiments, or gen-
erated by computational methods such as molecular
dynamics (MD) simulations [18]. Advances in experi-
mental techniques allowed a detailed view of biological
processes by accessing details of the structural proper-
ties of biological macromolecules [20]. These properties
can be further meticulously investigated by computa-
tional techniques such as MD simulations [21], which
simulate the motion phenomena of biological molecules
in atomic detail [22]. To consider the receptor flexibility
in molecular docking experiments the multiple receptor
conformations can be combined on different grid forms
or can be executed as a series of molecular docking
experiments, each of which with a different receptor
conformation.
According to Teodoro and Kavraki [18] the first use of
multiple structures derived from a MD simulation for a
drug design application was by Pang and Kozikowski
[23]. Carlson and co-workers [24] used the structures
from MD simulation to develop a receptor-based phar-
macophore where binding sites conserved during the
MD were combined into a dynamic pharmacophore
model. Lin et al. [25,26] presented the relaxed complex
scheme (RCS) to accommodate receptor flexibility in the
search for correct ligand-receptor conformations. They
first performed a MD simulation on the ligand-free pro-
tein and then docked ligands to snapshots obtained
from the simulation. More recently, Amaro et al. [27]
showed extensions and improvements to the RCS
method. They applied a more rigorous characterization
of local and global binding effects and improved the
computational efficiency by reducing the receptor
ensemble to a representative set of conformations.
Among all the available methodologies to model the
explicit flexibility of the receptor we chose to use an
ensemble of different receptor conformations derived
from a MD simulation trajectory. We call this a fully-
flexible receptor (FFR) model. Consequently, we must
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sidering in each one a receptor snapshot derived from
the MD trajectory. Despite that docking against several
structures increases the chances of finding a receptor in
the right conformational state to accommodate a parti-
cular ligand [17], this methodology can be compute-
intensive [12,13,15,16]. Several computer programs are
used in each receptor-ligand docking simulation and to
parameterize and execute all software, manually and
accurately, is not a trivial task [28].
Workflow modeling
Nowadays, workflows are not being used just for the
automation of business processes [29]: they are being
used successfully to automate scientific processes as well
[28,30-33]. Ludäscher et al. [30] define scientific work-
flows as a network of analytical steps, where the output
of a step is used as input for the next step, that can
involve access to and querying databases, data analysis
and mining, and other steps which, normally, are com-
putationally intensive jobs executed on high perfor-
mance computing platforms. According to Ludäscher et
al. [34] workflow development differs from general pro-
gramming mainly in that the composition and config-
uration of a workflow is built from pre-existing and
more general-purpose components, subflows and ser-
vices; a new workflow can be created by a user by modi-
f y i n ga ne x i s t i n go n e ,o re l s et h eu s e rc a nc o m p o s ea
new workflow using components and subflows obtained
from a repository. Moreover, scientific workflows may
include support for monitoring the execution of work-
flows in real time, recording the processing history and
allocation in distributed execution environments, and
managing scientific data [34]. All these features make up
for a much more complete and complex framework
which is arguably not available to a simple execution of
interactive scripts.
Some specific tools have already been developed to
model and execute scientific workflows, e.g. Kepler [30]
and Taverna [31]. Kepler is an open source tool
designed to implement and execute different varieties of
workflows ranging from low level workflows of interest
to grid engineers to analytical knowledge discovery
workflows for scientists [30]. Taverna [31] was specifi-
cally developed for the design and execution of bioinfor-
matics workflows in a structured, repeatable and
verifiable mode. Oinn et al. [31] described several other
scientific workflow management systems together with a
table comparing some features of these tools.
There already are a number of studies applying scientific
workflows to modeling and executing bioinformatics tasks
a n dn e wt o o l so re x t e n s i o n so fe x i s t i n go n e sa r eb e i n g
developed. For instance, BioMoby-based Web Services
[32] allow the construction of functional workflows,
defining ontology for bioinformatics data-types and a cor-
responding XML representation to facilitate the flow of
data from different Web-based resources. Bartocci et al.
[33] presents a new WfMS called BioWMS which provides
a Web-based user interface for definition, execution and
results management of a scientific experiment, employing
an agent-oriented technology to create a distributed, con-
current, flexible, adaptive and mobile system.
FReDoWS
Our test simulation is 3,100 ps (3,1 ns) long, with snap-
shots collected at every 1,0 ps. Thus, using the FFR
model, it is necessary to execute 3,100 molecular dock-
ing simulations. Executing all these simulations either
manually or using shell scripts is complicated and ineffi-
cient. Their results are likely not to be reproducible
when executed by different users at different times.
Moreover, there is the necessity to reduce the CPU
d e m a n d .T oa d d r e s st h i sp r o b l e m ,i nt h i sa r t i c l ew e
describe FReDoWS (Flexible-Receptor Docking Work-
flow System), a workflow-based methodology, developed
to automate molecular docking simulations that make
use of a FFR model. Additionally, a snapshot selection
feature was implemented to reduce the dimension of
FFR models so as to accelerate its application in virtual
screening of ligands [6].
Methods
The FReDoWs architecture
We adapted the WfMC [29] generic structure for a work-
flow to describe FReDoWS (Figure 1). Process design and
definition are prepared with JAWE2.0-2 [35]. Enhydra
Shark1.1-2 [36] is employed to instantiate and executes a
process. During each workflow execution of docking
simulation, Enhydra Shark interacts with C programs,
Swiss-PdbViewer (SPDBV) [37], AutoDock3.0.5 [7] and
AMBER6.0 [38] (other tools can be easily implemented
through a simple modification of the workflow model).
Process design and definition
During process design and definition we use the
JAWE2.0-2 [35] (Figure 1). JAWE2.0-2 is a visual tool
for creating, managing, and reviewing process definitions
in a straightforward and simple manner. It allows the
user to quickly create and verify workflow process defi-
nitions and store them for future use. It is also an activ-
ity-based WfMS in which processes (workflows) are
comprised of activities to be completed in order to
achieve a defined task [35]. JAWE has also been used in
other bioinformatics workflows projects [33].
Process instantiation and control
In the process instantiation and control, we chose to
use the Enhydra Shark1.1-2 [36] as our Workflow
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an extendable Java Open Source workflow engine that
includes a standard implementation completely based
on the WfMC [29] specifications using the XPDL lan-
guage. This workflow engine has implemented the
WfMC “ToolAgents” API to facilitate execution of
external applications as system activities. Both
JAWE2.0-2 [35] and Enhydra Shark1.1-2 [36] are free
software, execute in Linux and are easy to use. Figure
2a shows the main Enhydra Shark interface where the
user needs to upload the FReDoWS model that was
designed and defined by JAWE2.0-2. Subsequently the
process is instantiated by the user as illustrated in Fig-
ure 2b. In this step the process starts to be locally exe-
cuted by Enhydra Shark, with the activities released to
the user according to the workflow model (Figure 3).
One example is the generic activity depicted in Figure
2c. To be executed it needs to have some parameters
updated by the user (Figure 2d) for the variable R1. All
the FReDoWS activities are executed by C or Shell
Scripts the users do not need to know or modify. They
only need to set the variables for each activity, as
exemplified by Figure 2d, to perform the data prepara-
tion task. The user must specify the receptor and
ligand file names and their location. Afterwards, the
u s e rm u s ts e tw h a tk i n do fd o c k i n ge x p e r i m e n tw i l lb e
executed (exhaustive or selective) and thus other vari-
ables that are needed to perform each activity or
subflow.
Application tools
During process design and definition we modeled all
process activities, the majority of which needs to com-
municate with different application tools during each
workflow execution instantiation. The tools used in FRe-
DoWS are:
￿ Swiss-PdbViewer or SPDBV [37]: an application that
provides a graphical user interface allowing the analysis
of protein 3D structures. In our work, SPDBV is used to
position the ligand in the receptor binding site during
the step the ligand is prepared for the molecular dock-
ing simulation.
￿ AutoDock3.0.5 [7] is a suite of computer programs
for molecular docking.
￿ AMBER6.0 [38] is a suite of programs to minimize
and perform MD simulations on bio-molecules. It con-
sists of a substructure database, a force field parameter
file and also of a variety of utility programs. Ptraj, one
of its modules, processes the trajectory files generated
by MD simulations.
￿ In-house C programs and Shell scripts are used to
process data during the execution of the complete work-
flow and to generate the results tables, for instance, by
extracting information from AutoDock3.0.5 output files.
Full receptor flexibility from molecular dynamics
simulation
The receptor chosen for this study is the wild type InhA
(InhA_wt) enzyme [39] from Mycobacterium tuberculo-
sis and its mutants InhA_I21V and InhA_I16T, all three
in a binary complex with its native ligand, the coenzyme
NADH. The MD simulations of the InhA_wt-NADH,
InhA_I21V-NADH and InhA_I16T-NADH complexes
were performed for a time period of at least 3,100 ps
[40]. The NADH coenzyme was removed from the
InhA_wt and mutants’ MD trajectories for the docking
experiments. Thus, three FFR models of the unliganded
InhA_wt and two mutants were used in the experiments
below to validate the usefulness of FReDoWS.
Molecular docking experiments and computational infra-
structure
Each FFR InhA model was submitted to a docking
experiment using AutoDock3.0.5 [7]. During the execu-
tions, we used four types of computer architectures:
Cluster is a cluster of 7 PCs Pentium III 1,0 GHz and
256 MB RAM; PC1 is a Pentium 4 1,4 GHz and 512
MB RAM; PC2 is a Pentium 4 2,4 GHz and 1GB RAM;
PC3 is a Core 2 Quad 2,4 GHz and 8 GB RAM.
Results and discussion
FReDoWS – Flexible-Receptor Docking Workflow System
FReDoWS is an acronym for Flexible-Receptor Docking
Workflow System. It is a significant extension of the
Figure 1 Tools used in the development of FReDoWS. JAWE2.0-
2 is for process design and definition. Shark1.1-2 performs process
instantiation and control. FReDoWS interact with several software.
The Ptraj module of AMBER6.0 generates PDB files from MD
simulations. This is realized with C programs and shell scripts. Swiss-
PdbViewer (SPDBV) is used to visualize and manipulate receptor and
ligand structures and, finally, AutoDock3.0.5 is a suite of programs to
execute automated molecular docking experiments.
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Page 4 of 13Figure 2 Example of Shark’sI n t e r f a c e .(a) Main Enhydra Shark interface to upload workflow models. (b) Interface in Enhydra Shark to
instantiate a workflow process. (c) Example of workflow activity being executed by Shark in which it is necessary to update one variable. (d)
Example of Enhydra Shark Interface to update workflow variables.
Figure 3 Graphical representation of the FReDoWS model process developed in JaWE2.0-2[35]. Each type of activity corresponds to a
different color. The activities in green are executed by the user. Activities in purple indicate they are subflows, which in turn, represent a set of
other activities, such as internal transitions, participants, application definitions, and other workflow relevant data. Activities in lime are executed
by the system and with which the user can not interfere. This type of activity can invoke one or more external applications that are defined in
JaWE and executed by Shark through a WAPI (Workflows APIs and Interchange Formats). Finally, the activity in fuchsia is used for
synchronization and to formulate complex and sophisticated transitional conditions.
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includes a special snapshot selection feature. This fea-
ture is expected to accelerate automated docking experi-
ments with FFR models. Figure 3 is the JaWE [35]
internal representation of the FReDoWs workflow pro-
cess definition. In the workflow model that we devel-
oped there are two kinds of participants: Human and
System. The Human participant, represented in white
(Figure 3), indicates the workflow activities that need
human interference to be executed. For the System par-
ticipant, an automatic agent in blue (Figure 3), activities
are executed by the system without any human inter-
vention. FReDoWS follows a task-flow model which we
describe in Figure 3.
Setup task
Before the execution of FReDoWS there is a Setup task.
This step corresponds to the generation and storing of
instantaneous receptor conformations or snapshots
through the execution of a MD simulation of the recep-
tor. This task is not modeled in FReDoWS for it only
needs to be executed once for each receptor.
Data preparation task
This task involves the preparation of receptor and ligand
data. Before the execution of Prepare macro subflow
(Figure 3), the user needs to indicate whether it is
necessary to execute it in the activity Prepare recep y/n.
This step might not be necessary if the experiment only
employs a single receptor snapshot. In FReDoWS, the
Prepare macro subflow has two activities: (1) execution
of Ptraj to transform the MD trajectory files into the
PDB [5] format used by almost all docking software
[7-9], and (2) execution of a script to pick up snapshots
separated by time intervals larger than or equal to the
frequency with which snapshots are saved from the MD
simulation.
The ligand data preparation is executed by the Prepare
ligand subflow (Figure 3). As with the receptor prepara-
tion, before the execution of this subflow, the activity
Prepare lig y/n is executed. As the n option shows, it
may not be required to prepare the ligand if the docking
experiment employs the same receptor-ligand pair (for
instance when it is necessary to repeat or restart an
experiment). This subflow Prepare ligand has two activ-
ities: (1) places the ligand in its initial position within
the binding pocket of the FFR’s average structure.
Receptor and ligand structures are automatically opened
by Shark in Swiss-PdbViewer [37] and the ligand is
manually placed by the user in the receptor active site
and (2) the proper ligand file, in the Tripos Mol2 file (.
mol2), is generated and transformed into the PDBQ for-
mat by the autotors module of AutoDock3.0.5 [7]. Since
the data preparation tasks are executed by subflows,
they can be easily modified to run different docking
software and/or file formats through a relatively simple
update of these subflows, making FReDoWS a very flex-
ible system.
Execution of high-throughput molecular docking with FFR
models
FReDoWS allows the user to choose the kind of docking
experiments to execute. The user can run an exhaustive
docking experiment [28] where the FFR model is based
on the series of snapshots from a MD simulation trajec-
tory or a selective docking experiment. In the latter, it is
possible to selectively pick up particular snapshots from
the MD trajectory, trimming down the dimension of the
original FFR model, aiming at reducing the time neces-
sary for each FFR-ligand docking. Therefore, when the
activity Exhau or select? is called, the user can choose
the type of workflow execution.
In the activity Ask data exhau the user informs the
initial and final snapshots from the MD trajectory defin-
ing the FFR model and a counter value, which desig-
nates the next snapshot to be used (the counter value, a
check-pointing parameter, is a fault-tolerance feature
introduced to prevent a restart from the beginning in
case of workflow execution failure). Subsequently, FRe-
DoWS executes the activity Calc tot counter where the
total number of iterations of the subflow Execute dock-
ing is calculated based on the initial and final snapshots
positions. Following the process definition (Figure 3),
after the user indicates the type of execution, the pro-
cess spawns the subflow Execute docking (Figure 4)
where either experiment can be executed – exhaustive
or selective.
The first activity, Concat Param, is performed to con-
catenate the FFR model dimension to the parameters of
all following activities of this subflow. The activity Exe-
cute prep M prepares each individual snapshot file of
the FFR model for use in AutoDock3.0.5. As a result it
generates PDBQS files using the addsol utility. Execute
mkgpf3 and Execute mkdpf3 generates the input.gpf and
input.dpf files, respectively. These are the input files
necessary for the sequential execution of AGrid and
ADock .I fi ti st h ef i r s te x e c u t i o n ,i nPrep Docking the
file input.dpf is edited within the system’st e x te d i t o r
and the user can effortlessly modify the docking para-
meters. Execute AGrid executes the autogrid module.
Here grid maps are defined for each ligand atom type.
Execute ADock runs the autodock module. In this step
the interactions of each snapshot of FFR model and the
ligand are evaluated and estimates of their affinity are
calculated and expressed in terms of their free energy of
binding (FEB). At the end of each docking simulation an
output file is generated. It contains information about all
the tested ligand positions (conformation and orienta-
tion) organized according to the best FEB and the ligand
root mean square deviation (RMSD) to a reference posi-
tion. Compact Result, the last activity executed by the
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energies (FEB) and RMSDs output and stores them in a
results’ list.
Reducing the dimension of the FFR model: the snapshot
selection feature
The execution of an exhaustive experiment [28], using
the FFR model of InhA enzyme [39] and the ligand
molecule PIF takes about 100 hours of CPU time in the
Cluster. Since we envisage the execution of virtual
screening using FFR models of disease targets against
public databases of small molecules, such as ZINC [6],
containing over 13 million compounds, it is mandatory
to reduce the CPU time for each docking simulation.
T h es o l u t i o nw ep r o p o s ei sn o tt ou s et h ew h o l eM D
trajectory of the receptor, the FFR model, but rather a
sample of snapshots from it. We call this a reduced
fully-flexible receptor model (RFFR). In this work, as a
preliminary approach, we use the estimated FEB and the
RMSD values to reduce the dimension of the FFR
model.
After an exhaustive execution of a FFR-ligand docking
simulation, it is possible to execute new experiments
using the same receptor model, with different ligands
belonging to a single class (similar ligands), but on a
selection of snapshots from the trajectory. In this way
we hope to maintain the FFR model features and, at the
same time, reduce CPU time. In FReDoWS, to execute a
selective experiment, the user chooses the selection
option in the activity Exhau or select (Figure 3). The fol-
lowing Ask data select activity is performed. Its input
data are: Table T0, an output table obtained by the pre-
viously completed exhaustive experiment; Maximum
RMSD is the value of the RMSD that the user wants to
establish as one of the limiting parameters; Total Num-
ber of Snapshots is the number of snapshots to be
selected to build the RFFR model; Counter value is a
p o i n t e rt ot h es t a r to fe x e c u t i o n .N o w ,t h es e l e c t i o n
algorithm is ready to be executed by the activity Select
snaps.
Figure 5 presents a flowchart illustrating the snapshot
selection algorithm. Figure 6 shows the results for each
step in the algorithm. The result of the first step in the
selection algorithm is a table called T1 (Figure 6a), that
corresponds to T0, but organized in an ascendant order
according to FEB (Figure 6b). In the second step, T1 is
separated into two tables: T2 that corresponds to a table
in which the RMSD is smaller than the Maximum
RMSD and T3, which corresponds to the results with
RMSD larger than the Maximum RMSD. In this manner
we believe the selection method considers, at the same
time, the best FEB values together with the results with
acceptable RMSDs. In the third step, the algorithm tests
i ft h en u m b e ro fr o w si nT 2i ss m a l l e ro rg r e a t e rt h a n
the Total Number of Snapshots. If it is greater, the algo-
rithm bypasses all steps, except the last one, because all
Figure 4 Graphical representation of FReDoWS’ subflow Execute docking that executes the molecular docking simulations. We employ
the AutoDock3.0.5 [7] suite of C and AWK programs to execute docking experiments. The C programs are addsol, autotors, autogrid (AGrid) and
autodock (ADock) while mkgpf3 and mkdpf3 are the AWK scripts. The final model of this subflow contains eight activities which execute all steps
necessary for autodock (ADock) execution and the analyses of its output. See text for details.
Figure 5 Flowchart representation of the snapshot selection
algorithm. The algorithm is basically composed of four steps. First,
the original exhaustive result table is organized in an ascendant
order according to FEB. In the second step, this organized table is
split in to two others tables according to RMSD values. After that,
the final list of snapshots is completed and associations between
real snapshots and the ones used by Shark are created.
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if it is smaller, it is indispensable to complete T2 with
rows from T3. Finally, with the snapshots selection com-
pleted (T4 - Figure 6d), it is now necessary to create
associations between the real snapshots that are going
to be used (T4) and the snapshots called by Enhydra
Shark.
After the execution of Select snaps described above,
the activity Setup counter is executed with the starting
point of the counter assigned by the user. At last, the
Execute docking subflow shown before is performed and
all selective experiments are executed by FReDoWS.
Test cases
The test cases are aimed at validating FReDoWS and the
method for snapshots selection. We have previously exe-
cuted three exhaustive docking experiments using the
FFR model of InhA_wt and three ligands [28]. There-
fore, in this article we describe test cases using the snap-
shot selection feature of FReDoWS. These tests are
divided in two parts. The first part performs the selec-
tion directly from the exhaustive experiments described
by Machado et al. [28]. In the second part we use only a
sample of the snapshots, the RFFR model of the
InhA_wt and test it against a fourth, different ligand.
Finally, we describe test cases considering FFR models
of InhA_wt and the mutants InhA_I21V and InhA_I16T
with the ligand TCL, showing that FReDoWS can be
easily applied to different FFR models and different con-
figurations for the ligands (in these test cases we consid-
ered the TCL ligand flexible).
Before detailing these tests, we give a brief description
of the enzyme receptor and its FFR model, as well as
the ligands employed in the study.
The InhA enzyme and its FFR model
The InhA enzyme (or 2-trans-enoyl ACP-(CoA) Reduc-
tase, EC: 1.3.1.9) from Mycobacterium tuberculosis
(Mtb) represents an important target for tuberculosis
control [41]. Its inhibition disrupts the biosynthesis of
mycolic acids, which constitute essential structures for
bacterial survival [42]. Therefore, inhibitors targeting
this enzyme would be promising candidates for the
development of new drugs against tuberculosis [43].
InhA mutant strains have emerged almost at the same
time that isoniazid (INH) was first launched in the mar-
ket in the early 50’s as a first line drug for the treatment
of tuberculosis [44]. As an example, we have chosen to
work with the mutants I21V and I16T. These mutations
occur on a glycine-rich loop of InhA and were proved
to be correlated to INH resistance [40].
In the search for new inhibitors, several compounds
have been experimentally tested against Mtb’sI n h A
[45]. However, an automated method for in silico mole-
cular docking and virtual screening could turn this
Figure 6 Example of results from the snapshot selection algorithm. (a) Table T0 of results in the order of execution from the original
exhaustive docking simulations. (b) Table T1 of results assigned according to the FEB in an ascendant order. (c) T2 is the table of results in
which the minimum RMSD is smaller than the Maximum RMSD specified, while T3 contains results for which the RMSD is larger than the
Maximum RMSD. (d) T4 summarizes the list of receptor’s snapshots that will make up the FFR model with reduced dimension (RFFR model).
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of possible InhA ligands with improved inhibitory
effects.
Schroeder et al. [40] demonstrated in a series of MD
simulation studies that the InhA enzyme is a consid-
erably flexible macromolecule and that this flexibility
is reflected in its active site. Thus, we believe that for
a more realistic virtual screening, this flexibility
should be taken into account. For these reasons,
instead of using one single, rigid, crystal structure, we
use FFR models of InhA and mutants, obtained from
MD simulation trajectories of the InhA-NADH com-
plex [40].
The ligands NADH, PIF, TCL, and ETH
For the exhaustive test cases we used three ligands:
NADH [39], PIF [46] and TCL [45]. The nicotinamide
adenine dinucleotide (NADH) is the native ligand of
InhA. Therefore, it was considered as a reference ligand
for the docking evaluations. The NADH molecule has a
total of 71 atoms. Pentacyano(isoniazid)ferrate(II) or
PIF, the second ligand, contains 28 atoms. Triclosan or
TCL, is a molecule with 24 atoms. Both PIF [46,47] and
TCL [45] are considered good inhibitor candidates of
InhA. For the selective test case we consider one ligand,
Ethionamide or ETH. ETH is a small molecule com-
posed of 21 atoms. Like isoniazid, ETH only inhibits
InhA activity when covalently linked to NADH, forming
the adduct ETH￿NAD [44,48]. All ligands have at least
one rotatable bond.
The exhaustive test cases
FReDoWS successfully executed three different exhaus-
tive test cases [28] using AutoDock3.0.5 running the
simulated annealing protocol with 10 runs of execution,
each with 100 cycles. First the NADH ligand was
docked to the FFR model of InhA_wt. The FEB and
RMSD values, related to its well-known binding place
[40] in InhA, were collected. The same procedure was
repeated for PIF and the TCL ligands. The final results
are summarized in Table 1. For simplicity, in the
exhaustive test cases the ligands were considered rigid
during the molecular docking simulations. However, as
we show below, there is not much difference in using
flexible or rigid ligands.
For the FFR InhA-NADH complex, the docking simu-
lation for each snapshot took about 15 minutes to com-
plete running in the Cluster (see Material and Methods).
Hence, it took nearly 120 hours to execute the FFR of
InhA-NADH simulations. The results confirmed the
affinity of the NADH ligand for the InhA enzyme, show-
ing a good FEB average of -12.9 ± 4.2 kcal/mol. Since
we are performing blind docking, i.e., we do not know a
priori where the ligand should bind more efficiently in
the receptor, we cannot say much about the RMSD,
except that, for the FFR model, it indicates how freely
the ligand moved inside its flexible binding pocket.
However, as far as the FEB value is concerned, we know
it is a satisfactory one, for in a previous study [40], we
obtained a similar result for the average FEB using the
crystallographic position of NADH as the reference
ligand position to calculate the RMSD during the re-
docking simulations.
The FFR InhA-PIF complex docking simulations, also
executed in the Cluster, took around 100 hours of CPU
time. The shorter CPU time is justified on the basis that
PIF is significantly smaller than NADH. The FFR InhA-
PIF simulations resulted in a good average FEB with low
standard deviation (-9.9 ± 0.6 kcal/mol).Finally, for the
exhaustive test cases, the FFR InhA-TCL docking simu-
lations, executed in PC1 (see Material and Methods)
and took 500 hours of CPU time. The average FEB and
its standard deviation (-8,8 ± 0.3 kcal/mol) indicate a
favorable InhA-TCL association.
The selective test cases
In silico virtual screening for new inhibitor candidates
for any target receptor molecule takes a considerable
time when a single receptor structure is screened against
millions or tens of millions of compounds in a database,
(ZINC [6] , for instance). In a FFR model, as we [28]
and others [25,26] proposed, the CPU time to span a
database like ZINC should explode to an unachievable
cost. Hence, the necessity to reduce the CPU time for
docking simulations using a FFR model.
Given the above problem, we implemented a snapshot
selection feature in FReDoWS that accelerates docking
simulations which make use of FFR models derived
from a MD simulation trajectory. How does the selective

















NADH 71 -12.9 ± 4.2 2822 278 0 5.3 ± 2.2 Cluster 120
PIF 28 -9.9 ± 0.6 3041 0 59 5.0 ± 1.5 Cluster 100
TCL 24 -8.8 ± 0.3 2836 0 264 6.8 ± 1.8 PC1 500
The 3rd column shows the average and standard deviation of the FEB obtained with the FFR model of InhA. The 4th column shows the total number of docking
simulations that resulted in negative, favorable FEB values while the 5th column displays the unfavorable docking results with positive FEB. The 6th column
presents the number of docking simulation that did not converge. The 7th column presents the average RMSD and its variation about the ligand starting
position. The 8th and 9th columns show the computer architecture used and the CPU time for each FFR-ligand simulation.
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Page 9 of 13snapshot option of FReDoWS work? From the FFR
InhA-NADH docking simulations we selected the first
1,000 best-scored and posed (lowest FEB and RMSD)
docked InhA snapshots from the exhaustive FFR InhA-
N A D He x p e r i m e n t .N o w ,w eh a v et h eR F F Rm o d e lo f
InhA made of 1,000 snapshots only. We evaluate how
good this approach is compared to the complete FFR
model of InhA (composed of 3,100 snapshots). For that,
we observe the difference in FEB and RMSD between
the two approaches.
Three test cases were performed and divided in two
parts. In the first part we simply picked up the 1,000
best-scored snapshots for the FFR InhA-PIF and FFR
InhA-TCL complexes from their exhaustive docking
results (Table 2) based on the selection procedure
describe above. In the second part we used FReDoWS,
applying the selection feature, to execute selective dock-
ing experiments with the RFFR model of InhA-ETH
complex with the same docking protocol used in the
exhaustive test case.
All the selective test cases used the same 1,000 snap-
shots selected from the InhA-NADH results and, as the
exhaustive test cases, for simplicity, considered the
ligands rigid. It is worth stating, however, that the selec-
tion parameters used in this study were established for
our particular experiments and that they can be modi-
fied without difficulty according to one’s requirement.
F o rt h ef i r s tp a r to ft h es e l e c t i v ed o c k i n gt h eF F R
InhA-PIF test case had a FEB of -9.9 ± 0.6 kcal/mol and
aR M S Do f5 . 0±1 . 5Å( T a b l e1 ) .I nt h eR F F Ra n a l y s e s
we obtained a FEB of -9.9 ± 0.5 kcal/mol and a RMSD
of 4.8 ± 1.4 Å (Table 2). For the FFR InhA-TCL test
cases we obtained a FEB of -8.8 ± 0.3 kcal/mol and a
RMSD of 6.8 ± 1.8 Å (Table 1) while for the RFFR
model we obtained a FEB of -8.8 ± 0.3 kcal/mol and a
RMSD of 6.7 ± 1.7 Å (Table 2). Clearly, these experi-
ments are statistically similar; there is no significant dif-
ference between exhaustive (FFR model) and selective
(RFFR model) docking test cases.
In the second part, each complete InhA-ETH docking
simulation took 4 minutes of CPU time, and hence, a
total execution time of 80 hours for ETH in PC2. The
RFFR InhA-ETH had an average FEB of -6.7 ± 0.3 kcal/
mol and a RMSD of 5.2 ± 2.4 Å. Although greater than
the other FEB values, the InhA-ETH estimate of the
FEB is still an acceptable one. ETH is a small ligand
with only 21 atoms. Visual inspection with SPDBV [37]
shows that the ETH ligand can freely move in the
receptor binding pocket occupying, in most results, the
proper site to form the ETH￿NADH adduct that inhibits
the InhA enzyme activity [44,48].
Taken together, these data suggests that our selective
experiments, using the RFFR model, were successful
since they were able to reproduce the FEB values for the
first two ligands (PIF and TCL) using only 1,000 (RFFR
model) instead of 3,100 snapshots (FFR model) of the
InhA receptor and using only 1/3 of the CPU time. We
also obtained accurate results for the ETH ligand, for
which only the selective experiments were performed.
The total CPU time for this selective experiment in a
single computer was about 80 hours. If we had opted
for the FFR model this time would have a three-fold
increase.
Considering the analyses above, we can organize the
ligands in terms of the InhA receptor affinity for them.
We have found that the InhA receptor has better affinity
for the NADH (its innate coenzyme ligand), followed by
PIF, TCL, and ETH. From the experimental data avail-
able, we know that inhibition constant Ki for PIF is
0.086 µM [47,49] while for TCL it is 0.22 µM [45]. This
means that PIF has a better inhibitory effect than TCL
over the InhA receptor, corroborating our docking
results. As ETH inhibits the InhA receptor as the ETH￿-
NAD covalent adduct [50], it was expected that its FEB,
as a dissociated compound, would not give a good dock-
ing result as the previous ligands.
Overall, the results obtained with the selective test
cases for PIF, TCL and ETH suggests that, for these
classes of ligands, the FReDoWS snapshot selection fea-
ture was effective and could be applied more extensively
to other ligands to help accelerate the discovery of novel
inhibitors for Mtb’s InhA.
The exhaustive test cases considering three FFR models of
InhA
After executing the experiments with the ligands on a
rigid state, a new series of experiments were performed
using three FFR InhA models: the wild type (InhA_wt)
and the mutants InhA_I21V and InhA_I16T aiming at
comparing the binding modes in these models. MD
simulation trajectories for at least 3,100 ps for each

















PIF 28 -9.9 ± 0.5 1,000 0 0 4.8 ± 1.4 - -
TCL 24 -8.8 ± 0.3 1,000 0 0 6.7 ± 1.7 - -
ETH 21 -6.7 ± 0.3 984 0 16 5.2 ± 2.4 PC2 80
See Table 1 for details about the table contents.
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were tested against flexible TCL. The ligand flexibility
was determined with the autotors module of Auto-
Dock3.0.5 during FReDoWS execution, allowing two
torsion angles.
Docking was performed using AutoDock3.0.5, genetic
algorithm protocol with 25 runs, for which a maximum
number of 27,000 LGA was generated on the initial
population of 50 individuals, and a maximum number
of 500,000 energy evaluations. The results are summar-
ized on Table 3. Based on the standard deviations, small
but relevant differences can be seen in the experiments
of TCL with the different InhA receptor (wt, I21V and
I16T mutants). The average FEB varied from -13.1 ± 0.5
to -11.2 ± 0.7 to -12.7 ± 0.5 kcal/mol for InhA_wt,
InhA_I21V, InhA_I16T, respectively. The lowest FEB for
the crystal structure was -10.8 kcal/mol.
The FEB values described in Table 3 represent a dif-
f e r e n c eo fa b o u t2 . 5k c a l / m o lw h e nc o m p a r e dw i t ht h e
three FFR models. From this analysis we can state two
basic conclusions: first, the FFR models were able to dis-
criminate the InhA affinity for the TCL ligand. They
showed that TCL binds more strongly to InhA_wt than
to the mutants. Second, FFR models can accommodate
a more diverse range of ligand conformations. This indi-
cates that they are more prone to select a new ligand
capable of binding to InhA than it would do if we used
only a single crystal, rigid structure.
Conclusions
T h em a i nc o n t r i b u t i o no fo u ra r t i c l ei sF R e D o W S ,a
workflow-based methodology to automate the molecular
docking processes using a FFR model. FReDoWS
includes a snapshot selection feature to further acceler-
ate the virtual screening of ligands for well defined dis-
ease targets. FReDoWS was developed using JAWE and
Shark software tools to model and execute processes,
respectively. It can be defined as a scientific workflow
because it handles complex objects and files and exe-
cutes complex and long-running activities. It strictly
controls activities executions based on a complete work-
flow model, decides the next steps based on output
values produced by activities and, indeed, selects differ-
ent execution branches with such values.
FReDoWS usefulness was demonstrated by the investi-
gation of the docking of four different ligands to the
Mycobacterium tuberculosis InhA enzyme. We found
that all four ligands binds effectively to the InhA FFR
model as expected from the literature on similar, but
wet experiments. We can also determine the extent of
the receptor flexibility, and accelerate the docking
screening, by performing docking simulations with
selection of snapshots (the RFFR model). A work that
would usually need the manual execution of many com-
puter programs, including the docking software Auto-
Dock3.0.5, and the manipulation of thousands of files,
was efficiently and automatically performed by FRe-
DoWS. In order to perform the same experiments with-
out FReDoWS, one would have to be familiar with
programming languages, shell scripts, command-line
tools and so on. Development of these skills is time con-
suming and not trivial. We have demonstrated that, with
a graphical user interface, the user can perform those
tasks without hassling with technical details of the many
tools involved. FReDoWs friendly interface allows the
user to change the docking and execution parameters
according to the necessity. In particular, the snapshots
selection method described in this work was simple
enough to illustrate the functioning of FReDoWS. As
future work we will develop and analyze different snap-
shot selection criteria to further reduce the dimension
of the FFR models, generating a much more refined
RFFR while still maintaining the explicit flexibility of the
receptor. We expect these advances to bring down the
CPU time to a level that can allow the routine use of
FFR or RFFR models in virtual screening of millions of
compounds. Finally, with FReDoWS and our FFR
model, defined by a collection of snapshots derived
from a MD simulation trajectory, we expect to explore
more of the role flexibility plays in receptor-ligand
interactions.
List of abbreviations
FReDoWS: Flexible-Receptor Docking Workflow System; FEB: Free Energy of
Binding; FFR: Fully-Flexible Receptor; MD: Molecular Dynamics; RDD: Rational
Drug Design; PDB: Protein Data Bank; RCS: Relaxed Complex Scheme; RFFR:
Reduced Fully-Flexible Receptor Model; RMSD: Root Mean Square Deviation;
WfMS: Workflow Management System.
Table 3 Results for the exhaustive test cases considering three FFR models of the InhA receptor














InhA_wt TCL -13.1 ± 0.5 3,100 0 0 6.6 ± 2.1 PC3 72
InhA_I21V TCL -11.2 ± 0.7 3,100 0 0 5.6 ± 1.5 PC3 72
InhA_I16T TCL -12.7 ± 0.5 3,100 0 0 6.4 ± 1.3 PC3 72
The first column describes the receptor FFR model. The second column shows the considered ligand. See Table 1 for details about the other columns table
contents.
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